Relationship between nitric oxide and early ischemic brain damage induced by photochemistry in rats and the protective effects of gypenosides on the damage1

Abstract

Abstract: AIM: To investigate the relationship between nitric oxide (NO) and early ischemic brain damage induced by photochemistry and the effect of gypenosides (Gyp) on the damage. METHODS: The effects of Gyp and oxidized hemoglobin (OHb) on ischemic brain tissure areas, TBARS and H₂O contents, superoxide dismutase (SOD) activity and NO level were observed on the rat middle cerebral artery occlusion (MCAO) model induced by photochemistry. RESULTS: The middle cerebral artery occlusion for 6 h caused obvious ischemic brain damage, increased the areas of ischemic brain and the contents of H2O and TBARS, and decreased SOD activity and NO level (all P <0.05).These effects can be exacerbated seriously by OHb, but reversed by Gyp. CONCLUSION: The decrease of early cerebral NO level is an important factor to lead to ischemic brain damage.Gyp decreases ischemic brain damage by increasing early cerebral NO level and has a prophylactic protective effect on cerebral ischemic damage.

Key words: pharmacology, gypenosides, photochemistry, ischemic brain damage, nitric oxide

CLC Number:

XIE Zhi-Zhong, ZHU Bing-Yang, TANG Xiao-Qing, LIAO Duang-Fang, YU Lin. Relationship between nitric oxide and early ischemic brain damage induced by photochemistry in rats and the protective effects of gypenosides on the damage1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 282-285.

References

[1] Iadecola C.Bright and dark sides of nitric oxide in ischemic brain injury[J].Trends Neurosci, 1997;20:132-9
[2] Tarkowski E, Ringqvist A, Rosengren L, et al.Intrathecal release of nitric oxide and its relation to final brain damage in patients with stroke[J].Cerebrovasc Dis, 2000;10:200-6
[3] Coyle P.Middle cerebral artery occlusion in the young rat[J]. Stroke, 1982;13:855
[4] Marc F, Julio HG.Evolving stroke and the ischemic penumbra [J].Neurology, 1996;47:884
[5] 孙云, 张洪泉.脂质过氧化产物的测定方法[A].孙云, 沈乃, 张洪泉, 等.超氧化物歧酶测定法之六— 邻苯三酚法[A].见:徐叔云, 卞如濂, 陈修, 主编.药理实验方法学[M].第3 版.北京:人民卫生出版社, 2002;431-2;535-6
[6] Iadecola C, Zhang F, Xu X.Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage[J].Am J Physiol, 1995;268:286-92
[7] Nagayama M, Zhang F, Iadecola C.Delayed treatment with aminoguanidine decrease focal cerebral ischemic damage and enhances neurologic recovery in rats[J].J Cereb Blood Flow Metab, 1998;18:1107-13
[8] Iadecola C, Zhang F, Casey R, et al.Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene[J].J Neurosci, 1997; 17:9157-64
[9] 帅杰, 董为伟.不同脑缺血和再灌流过程中大鼠脑组织NO 含量的动态变化[J].临床神经病学杂志, 1997;10:326-8
[10] Zhang F, Xu S, Iadecola C.Time dependence of effect of nitric oxide synthase inhibition on cerebral ischemic damage[J]. J Cereb Blood Flow Metab, 1995;15:595-601
[11] 陈剑雄, 唐小卿, 朱炳阳, 等.外源性氧自由基所致脑基底动脉痉挛的机制[J].中国动脉硬化杂志, 1994;2;88-91
[12] 陈剑雄, 曾恒, 唐小卿, 等.光化学诱导大脑中动脉栓塞后脑组织水、阳离子及脂质过氧化物含量的变化[J].南华大学学报(医学版), 1996;24:262-5

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[3]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[4]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[5]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[6]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[7]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[8]	LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying. Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
[9]	YAO Qian, CHEN Yun, SHANG Juan, XI Xiaoyun, CHEN Ying, GU Xiao, JU Wenzheng, ZOU Jiandong, LU Su, XU Meijuan. Investigation of potential pharmacodynamic substances and mechanism of Qingxin-zishen prescription decoction in treatment of menopause syndrome based on HPLC-Q-TOF-MS/MS and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 481-497.
[10]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[11]	XIE Mengdie, WANG Chenchen, LI Bingtao, OUYANG Changsheng, QIU Yumei, LI Hongming, TU Jun, SHANG Guangbin, TANG Xilan. Analysis on mechanism of frankincense volatile oil in prevention and treatment of cardiac hypertrophy based on in vitro cell experiment and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 241-252.
[12]	CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong. Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
[13]	WANG Jinhuo, GUO Jianrong. Clinical pharmacological properties of alfentanil and its progress in anesthetic application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 824-829.
[14]	ZHANG Ningyuan, ZHENG Xijun, XU Ling, LIU Hongxia, ZHENG Qingshan. Disease progression model for Alzheimer's disease and its research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 687-694.
[15]	YU Tianyi, JIAO Guangyang, HUANG Doudou, CHEN Yong, XU Deduo, QIU Shi, CHEN Wansheng, ZHANG Feng, WANG Bolong. Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1127-1145.